GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$80.12
4.16 (5.48%)
▲
5d:
-5.35%
30d:
+2.39%
90d:
-8.68%
HOLD
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
30d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMED shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$130.91
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$81.29
1.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $80.12, which is considered fair relative to its 30-day fair value range of $77.78 to $83.06. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.6) compared to its historical average (18.8). Remarkably, the market is currently pricing in an annual earnings decline of 6.1% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a strong downtrend. Immediate support is located at $75.14, while resistance sits at $86.34. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $108.64 (+35.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMED is in a strong downtrend. Immediate support is located at $75.14, while resistance sits at $86.34. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $108.64 (+35.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$77.78 -
$83.06
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.5%)
- BULLISH: Trading 35.6% below Wall St target ($108.64)
- CAUTION: Recommendation downgraded due to -5.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$77.78 -
$83.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$75.14
Resistance Level
$86.34
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.57
Wall Street Target
$108.64
(+35.6%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-6.1% cheaper
PE vs Historical
15.6 vs 18.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.1%
(market-implied from PE analysis)
1-Year Target
$75.23
(-6%)
2-Year Target
$70.64
(-12%)
3-Year Target
$66.33
(-17%)
3-Yr Target (if PE normalizes)
(PE: 16→19)
$80.09
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.5%)
$143.07
(+79%)
Base:
(SPY PE: 15.6, Growth: 8.5%)
$102.28
(+28%)
Bear:
(PE: 13.2, Growth: 8.5%)
$86.94
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 17.75 | Current EPS (TTM): $4.28
Bull Case
$100.45
(+25%)
Analyst growth 20.2%, PE expands to 19.5
Base Case
$91.32
(+14%)
Market implied 20.2%, PE stable at 17.8
Bear Case
$51.65
(-36%)
Severe decline -20.0%, PE contracts to 15.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.6 to 18.8
Stabilization Target:
$96.73
(+20.7%)
PE Expansion Potential:
+20.7%
Share & Embed Analysis
Last updated: July 05, 2026 7:09 PM ET
Data refreshes hourly during market hours. Next update: 8:09 PM
Data refreshes hourly during market hours. Next update: 8:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
